Myriad RBM, a wholly-owned subsidiary of molecular diagnostic company Myriad Genetics Inc. ( MYGN ), has recently collaborated with global pharmaceutical products maker Sanofi ( SNY
Ingersoll-Rand Plc ( IR ) reportedly is planning to divest its security technology business. The Security Technology business recorded sales of $391 million in the third quarter of